Fostamatinib
Fostamatinib is a tablet that blocks the enzyme SYK so the spleen stops destroying antibody-coated platelets; it is approved for chronic immune thrombocytopenia and was first trialled as a lymphoma drug.
Overview
Fostamatinib is an oral SYK inhibitor approved in the United States in 2018 for adults with chronic immune thrombocytopenia (ITP) who have not responded to a previous treatment. SYK sits downstream of the B-cell receptor and of Fc receptors, and fostamatinib was originally studied in B-cell lymphomas and chronic lymphocytic leukaemia, where responses were modest and the programme moved to autoimmune disease. Its place in cancer care is therefore supportive: managing immune-mediated low platelets, including in patients whose ITP accompanies lymphoid cancers. Hypertension, diarrhoea and raised liver enzymes are the main side effects.
A prodrug converted to R406, which inhibits SYK and so blocks the antibody-triggered destruction of platelets by macrophages in the spleen.
1.Fostamatinib slips into a pocket on its target.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Fostamatinib" OR ABSTRACT:"Fostamatinib" OR TITLE:"Tavalisse" OR ABSTRACT:"Tavalisse" OR TITLE:"Fostamatinib Disodium" OR ABSTRACT:"Fostamatinib Disodium" OR TITLE:"R788" OR ABSTRACT:"R788" OR TITLE:"R935788" OR ABSTRACT:"R935788") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fostamatinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentEltrombopag
Shares Thrombocytopenia and the tags gap-fill, supportive-care.
- TreatmentRomiplostim
Shares Thrombocytopenia and the tags gap-fill, supportive-care.
- TreatmentEmapalumab
Shares Diffuse large B-cell lymphoma and the tags gap-fill, supportive-care.
- TreatmentPropranolol (Hemangeol)
Shares the tags gap-fill, supportive-care.
- TreatmentRavulizumab
Shares the tags gap-fill, supportive-care.
- TreatmentUmbralisib
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag gap-fill.
- TreatmentIdelalisib
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag gap-fill.
- TreatmentDuvelisib
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag gap-fill.